We will discuss the principles of how FcγRIIB-dependent TNFRSF agonistic antibodies can be engineered to induce receptor clustering and activation optimally in the tumor microenvironment while minimizing systemic toxicity. The gene discussed is FCGR2B; the disease is neoplasm.